ArticleProteomics. Clinical applications2010
Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray.
Article in Proteomics. Clinical applications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.Clinical and translational science · 2023Pooled it
- Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.Scientific reports · 2017Trial
- Unlocking the Potency of Keyhole Limpet Hemocyanin: Structural Insights, Immunological Mechanisms, and Therapeutic Frontiers.International journal of molecular sciences · 2026Review
- A Biomimetic Self-Adjuvanting Glycoprotein Vaccine Platform Elicits Potent Antitumor Immunity against GD2-Positive Cancers.JACS Au · 2026Article
- Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia.Vaccines · 2025Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Article
- Molluskan Hemocyanins Activate the Classical Pathway of the Human Complement System through Natural Antibodies.Frontiers in immunology · 2017Article
- Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins.Cell chemical biology · 2016Article
- High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge.PloS one · 2013Article
- Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Metabolites · 2012Article
- Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.Cancer immunology, immunotherapy : CII · 2012Article
- Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.Bioconjugate chemistry · 2012Article
- An array-based method to identify multivalent inhibitors.Journal of the American Chemical Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purposeKeyhole limpet hemocyanin (KLH) is used as a vaccine adjuvant, as a carrier protein for small haptens, and as a treatment for bladder cancer. Immunization with KLH produces antibodies to tumor-associated carbohydrate antigens (TACAs) in animals, and these antibodies have been postulated as the basis of efficacy for bladder cancer treatment. The purpose of this study was to evaluate antibody responses to KLH in humans. EXPERIMENTAL
designA carbohydrate microarray was used to profile antibody responses in 14 individuals immunized with KLH plus alum adjuvant.
resultsEight out of fourteen individuals produced antibodies to at least one TACA. Increases to Lewis X, Lewis Y, GA1di, GM3, and sialyl Lewis A were observed in certain individuals, but, in general, antibody profiles were highly variable. Pre-immunization antibody levels to a subset of array antigens had a statistically significant correlation with the magnitude of the antibody response to KLH. CONCLUSIONS AND CLINICAL RELEVANCE: Antibodies to TACAs can be produced in humans, but antibody profiles differ considerably from person to person, which may contribute to variable clinical responses with KLH. Pre-treatment antibody levels to certain antigens may be useful for predicting which patients will respond favorably to KLH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.